By Thomas Hofmarcher, Anne Leppänen, Anna Månsdotter, Joakim Strandberg, Anders Håkansson

Background: Illegal drug use is a public health concern with far-reaching consequences for people who use them and for society. In Sweden, the reported use of illegal drugs has been growing and the number of drug-induced deaths is among the highest in Europe. The aim of this study was to provide a comprehensive and up-to-date estimation of the societal costs of illegal drug use in Sweden, relying as much as possible on registry and administrative data. Methods: A prevalence-based cost-of-illness study of illegal drug use in Sweden in 2020 was conducted. A societal approach was chosen and included direct costs (such as costs of health care, social services, and the criminal justice system), indirect costs (such as lost productivity due to unemployment and drug-induced death), and intangible costs (such as reduced quality of life among people who use drugs and their family members). Costs were estimated by combining registry, administrative, and survey data with unit cost data. Results: The estimated societal costs of illegal drug use were 3.7 billion euros in 2020. This corresponded to 355 euros per capita and 0.78 % of the gross domestic product. The direct and intangible costs were of similar sizes, each contributing to approximately 40 % of total costs, whereas indirect costs contributed to approximately 20 %. The largest individual cost components were reduced quality of life among people who use drugs and costs of the criminal justice system. Conclusion: Illegal drug use has a negative impact on the societal aim to create good and equitable health in Sweden. The findings call for evidence-based prevention of drug use and treatment for those addicted. It is important to address the co-morbidity of mental ill-health and drug dependence, to develop low-threshold services and measures for early prevention among children and young adults, as well as to evaluate laws and regulations connected to illegal drug use.

International Journal of Drug Policy, Volume 123, January 2024, 104259

By The United Nations Office on Drugs and Crime

Restrictions on movement imposed by govern- ments across the world due to the COVID-19 pandemic have had an impact on the trafficking of substandard and falsified medical products. Interpol and the World Customs Organization (WCO) reported that seizures of substandard and falsified medical products, including person- al protective equipment (PPE), increased for the first time in March 2020. The emergence of trafficking in PPE signals a significant shift in organized criminal group behaviour that is directly attributable to the COVID-19 pandemic, which has brought huge demand for medical products such as PPE over a relatively short period of time. It is foreseeable that, with the evolution of COVID-19 and developments in medicinal treatments and/or the repurposing of existing medicines, criminal behaviour will shift from trafficking in PPE to the development and delivery of a COVID-19 vaccine. Furthermore, cyberattacks on critical infrastructure involved in addressing the pandemic are likely to continue in the form of online scams aimed at health procurement authorities. Challenges in pandemic preparedness, ranging from weak regulatory and legal frameworks to the prevention of the manufacturing and trafficking of substandard and falsified products and cyber security shortcomings, were evident before COVID-19, but the pandemic has exacerbated them and it will be difficult to make significant improvements in the immediate short term. The report concludes that crime targeting COVID-19 medical products will become more focused with significantly greater risks to pub- lic health as the containment phase of the pan- demic passes to the treatment and prevention stages.

Vienna: UNODC Research and Trend Analysis Branch. 2020. 31p